Fortune MNC 500 India 2026 edition
Rank#284- Total income
- ₹2,090 Cr
- Profit
- ₹116 Cr
Last year #313
Astrazeneca Pharma India Limited - pharma in Bangalore, Karnataka, India. FY 2026 financials & compliance.
Active Listed - NSE: ASTRAZEN · BSE: 506820 Public Limited Company pharma Fortune MNC 500 · #284 BSE 500
Market Cap
₹16,286 Cr
ASTRAZEN · NSE
Share Price
₹6,514.50
+0.54% today
Revenue
₹2,276 Cr
FY 2025-26 · +32.6% YoY
EBITDA
₹257 Cr
Margin 11.3%
Net Profit
₹191 Cr
FY 2025-26 · +9.2% YoY
P/E (TTM)
84.7x
P/B 18.1x
ROE
22.8%
ROCE 27.9%
Debt / Equity
0.09
Interest cover 2.0x
About Astrazeneca Pharma India Limited
Data last updated:
Astrazeneca Pharma India Limited is a public limited company based in Bangalore, Karnataka, India, a subsidiary of Astrazeneca Pharmaceuticals Ab. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 11 July 1979 and has been in existence for over 47 years.
Astrazeneca Pharma India is ranked #284 on the Fortune MNC 500 India (2026). It is part of the BSE 500 index.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN L24231KA1979PLC003563. Its GSTIN is 29AABCA1722B1ZC (Karnataka). The company holds 22 GST registrations, of which 11 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 506820 and NSE: ASTRAZEN.
The company has an authorised share capital of ₹5 Cr and a paid-up capital of ₹5 Cr. It was formerly known as Astra Idl Limited. It is led by directors including Praveen Rao Akkinepally (Managing Director) and Bhavana Agrawal (Whole-Time Director).
Its last annual general meeting (AGM) was held on 14 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Block N1 12th Floor Manyata Embassy Business Park Rachenahalli Outer Ring Road, Bangalore, Karnataka, India – 560045.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹2,275.58 Cr, a growth of 32.6% compared to the previous year. For the same year it recorded a net profit of ₹191.31 Cr (net margin 8.4%) and EBITDA of ₹256.78 Cr (EBITDA margin 11.3%). The net worth stands at ₹872.79 Cr (up 13.3% YoY). Total assets are valued at ₹1,021.2 Cr (up 24.3% YoY).
The company has about 935 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Astrazeneca. As per MCA filings, the company has satisfied charges of ₹62.5 Cr on record. Court records list 276 cases involving the company, including 150 filed by the company and 126 filed against it; 50 cases are pending. The company has 8 deals on record (7 market trades, 1 acquisition); the latest was in October 2024. Its 4 peer companies in the Pharma industry (Formulations), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations) are compared by revenue, 3 larger and 1 smaller; the largest is FDC Limited with revenue of ₹2,198.78 Cr. The company has 11 MSME Form 1 returns on record between 2019 and 2024, listing 77 overdue payments to 29 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website astrazeneca.in.
Company details
CIN L24231KA1979PLC003563
Registration Number 003563
Incorporation Date 11 July 1979
ROC Bangalore
Listing Status Listed - Listed on NSE (ASTRAZEN); Listed on BSE (506820)
Company Status Active
Date of Last AGM 14 August 2025
Date of Balance Sheet 31 March 2026
Parent Company Astrazeneca Pharmaceuticals Ab
Compliance Status Active Compliant
CIN history
Astrazeneca Pharma India has one previous CIN (Corporate Identification Number): L85110KA1979PLC003563. The current CIN is L24231KA1979PLC003563, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24231KA1979PLC003563 | Current |
| L85110KA1979PLC003563 | Previous |
Key People
Praveen Rao Akkinepally Managing Director Bhavana Agrawal Whole-Time Director Shilpa Divekar Nirula Director Recognitions & Rankings of Astrazeneca Pharma India
Stock market indices
BSE 500
Contact details
Astrazeneca Pharma India Limited's registered office is in Bangalore, Karnataka. Its website is astrazeneca.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressBlock N1 12th Floor Manyata Embassy Business Park Rachenahalli Outer Ring Road, Bangalore, Karnataka, India – 560045
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Astrazeneca Pharma India Limited, buy the company report.
Comprehensive company report
Astrazeneca Pharma India Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Astrazeneca Pharma India operates one associated brand: Astrazeneca. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical and biologics products are developed and distributed worldwide. | astrazeneca.com |
Business activity
The main business activity of Astrazeneca Pharma India is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | 21 | Manufacture of basic pharmaceutical products and pharmaceutical preparations |
To see the full business activity and turnover split of Astrazeneca Pharma India Limited, buy the company report.
Financials of Astrazeneca Pharma India Limited
FY 2025-26 filings availableAstrazeneca Pharma India Limited reported revenue of ₹2,275.58 Cr (up 32.6% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue
₹2,276 Cr
+32.6% YoY
EBITDA
₹257 Cr
+63.4% YoY
Profit After Tax
₹191 Cr
+9.2% YoY
Net Worth
₹873 Cr
+13.3% YoY
Total Assets
₹1,021 Cr
+24.3% YoY
Total Debt
₹111 Cr
+209.7% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 2,276 | 1,716 | 1,296 | 1,003 | 806 | 814 | 832 |
| Revenue growth | +32.6% | +32.5% | +29.2% | +24.5% | -1.0% | -2.2% | - |
| EBITDA | 257 | 157 | 184 | 125 | 86.18 | 135 | 121 |
| EBITDA margin | +11.3% | +9.2% | +14.2% | +12.5% | +10.7% | +16.7% | +14.5% |
| Profit before tax | 252 | 156 | 220 | 134 | 83.04 | 127 | 114 |
| Net profit | 191 | 175 | 149 | 126 | 59.55 | 91.72 | 72.03 |
| Net profit margin | +8.4% | +10.2% | +11.5% | +12.6% | +7.4% | +11.3% | +8.7% |
| EPS (₹) | 75.01 | 46.30 | 64.60 | 39.72 | 24.64 | 37.32 | 28.88 |
| Balance sheet | |||||||
| Total assets | 1,021 | 821 | 723 | 604 | 528 | 475 | 382 |
| Net worth | 873 | 770 | 712 | 589 | 511 | 456 | 364 |
| Total debt | 111 | 35.73 | 4.59 | 7.21 | 8.63 | 12.14 | 11.84 |
| Cash & bank | 449 | 537 | 506 | 500 | 448 | 352 | 253 |
| Net working capital | 772 | 646 | 577 | 455 | 377 | 319 | 218 |
| Cash flow | |||||||
| Cash from operations | (15.14) | 65.36 | 27.87 | 58.29 | 101 | 105 | 87.42 |
| Cash from investing | 18.69 | 30.80 | 21.74 | 18.11 | 4.74 | 173 | (171) |
| Cash from financing | (91.97) | (65.59) | (44.38) | (24.48) | (9.46) | (8.97) | (6.36) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 729 | 683 | 579 | 612 | 559 | 526 | 480 | 440 |
| Revenue growth (YoY) | +30.4% | +29.7% | +20.4% | +38.9% | +37.0% | +35.8% | - | - |
| Other income | 15.12 | 9.23 | 5.95 | 6.61 | 6.17 | 11.24 | 16.15 | 7.98 |
| Total expenses | 648 | 634 | 519 | 567 | 489 | 446 | 400 | 397 |
| EBITDA | 80.61 | 48.70 | 59.83 | 44.83 | 69.89 | 80.75 | 80.69 | 43.44 |
| EBITDA margin | +11.1% | +7.1% | +10.3% | +7.3% | +12.5% | +15.3% | +16.8% | +9.9% |
| Depreciation | 5.35 | 5.23 | 5.60 | 3.84 | 2.57 | 16.57 | 17.69 | 9.07 |
| Interest | 1.89 | 1.95 | 2.04 | 1.06 | 0.67 | 0.72 | 0.68 | 0.33 |
| Profit before tax | 88.49 | 50.75 | 58.14 | 46.54 | 72.82 | 74.70 | 78.47 | 42.02 |
| Tax | 26.16 | 12.82 | 13.26 | 13.95 | 18.60 | 18.87 | 20.22 | 11.17 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 10 Nov 2026
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 729 | 683 | 579 | 612 | 559 | 526 | 480 | 440 |
| Revenue growth (YoY) | +30.4% | +29.7% | +20.4% | +38.9% | +37.0% | +35.8% | - | - |
| Other income | 15.12 | 9.23 | 5.95 | 6.61 | 6.17 | 11.24 | 16.15 | 7.98 |
| Total expenses | 648 | 634 | 519 | 567 | 489 | 446 | 400 | 397 |
| EBITDA | 80.61 | 48.70 | 59.83 | 44.83 | 69.89 | 80.75 | 80.69 | 43.44 |
| EBITDA margin | +11.1% | +7.1% | +10.3% | +7.3% | +12.5% | +15.3% | +16.8% | +9.9% |
| Depreciation | 5.35 | 5.23 | 5.60 | 3.84 | 2.57 | 16.57 | 17.69 | 9.07 |
| Interest | 1.89 | 1.95 | 2.04 | 1.06 | 0.67 | 0.72 | 0.68 | 0.33 |
| Profit before tax | 88.49 | 50.75 | 58.14 | 46.54 | 72.82 | 74.70 | 78.47 | 42.02 |
| Tax | 26.16 | 12.82 | 13.26 | 13.95 | 18.60 | 18.87 | 20.22 | 11.17 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 2,276 | 1,716 | 1,296 | 1,003 | 806 | 814 | 832 |
| Revenue growth | +32.6% | +32.5% | +29.2% | +24.5% | -1.0% | -2.2% | - |
| Other income | 28.49 | 40.63 | 51.23 | 26.10 | 14.76 | 12.84 | 12.99 |
| Total expenses | 2,019 | 1,559 | 1,111 | 878 | 719 | 678 | 711 |
| Employee cost | 264 | 257 | 241 | 259 | 230 | 220 | 217 |
| EBITDA | 257 | 157 | 184 | 125 | 86.18 | 135 | 121 |
| EBITDA margin | +11.3% | +9.2% | +14.2% | +12.5% | +10.7% | +16.7% | +14.5% |
| Depreciation | 28.58 | 39.99 | 14.94 | 16.26 | 16.95 | 20.13 | 18.58 |
| Interest | 4.49 | 1.46 | 1.20 | 0.63 | 0.95 | 1.09 | 1.14 |
| Profit before tax | 252 | 156 | 220 | 134 | 83.04 | 127 | 114 |
| Tax | 64.68 | 40.62 | 58.03 | 34.81 | 21.44 | 33.79 | 41.76 |
| Net profit | 191 | 175 | 149 | 126 | 59.55 | 91.72 | 72.03 |
| Net profit margin | +8.4% | +10.2% | +11.5% | +12.6% | +7.4% | +11.3% | +8.7% |
| EPS (₹) | 75.01 | 46.30 | 64.60 | 39.72 | 24.64 | 37.32 | 28.88 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Reserves & surplus | 868 | 765 | 707 | 584 | 506 | 451 | 359 |
| Shareholders' funds (net worth) | 873 | 770 | 712 | 589 | 511 | 456 | 364 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 111 | 35.73 | 4.59 | 7.21 | 8.63 | 12.14 | 11.84 |
| Total debt | 111 | 35.73 | 4.59 | 7.21 | 8.63 | 12.14 | 11.84 |
| Total liabilities | 1,021 | 821 | 723 | 604 | 528 | 475 | 382 |
| Assets | |||||||
| Gross block | 185 | 218 | 187 | 179 | 169 | 160 | 133 |
| Net block | 117 | 64.24 | 66.68 | 68.86 | 74.49 | 80.96 | 71.53 |
| Capital work in progress | 0.00 | 0.00 | 0.27 | 1.33 | 2.20 | 4.02 | 24.24 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 1,027 | 548 | 228 | 190 | 140 | 160 | 165 |
| Sundry debtors | 214 | 185 | 153 | 108 | 85.89 | 85.19 | 83.21 |
| Cash & bank balances | 449 | 537 | 506 | 500 | 448 | 352 | 253 |
| Loans & advances | 50.30 | 72.27 | 45.86 | 37.26 | 31.10 | 21.42 | 41.44 |
| Total current assets | 1,740 | 1,342 | 933 | 835 | 706 | 619 | 542 |
| Total current liabilities | 968 | 697 | 355 | 380 | 329 | 300 | 325 |
| Net working capital | 772 | 646 | 577 | 455 | 377 | 319 | 218 |
| Total assets | 1,021 | 821 | 723 | 604 | 528 | 475 | 382 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 536 | 506 | 500 | 448 | 352 | 83.50 | 173 |
| Net cash from operating activities | (15.14) | 65.36 | 27.87 | 58.29 | 101 | 105 | 87.42 |
| Net cash from investing activities | 18.69 | 30.80 | 21.74 | 18.11 | 4.74 | 173 | (171) |
| Net cash from financing activities | (91.97) | (65.59) | (44.38) | (24.48) | (9.46) | (8.97) | (6.36) |
| Net change in cash | (88.42) | 30.57 | 5.23 | 51.92 | 96.08 | 269 | (89.74) |
| Closing cash | 449 | 537 | 506 | 500 | 448 | 352 | 253 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +32.6% | +32.5% | +29.2% | +24.5% | -1.0% | -2.2% | - |
| EBITDA growth | +63.4% | -14.8% | +47.7% | +44.9% | -36.4% | +12.2% | - |
| PBT growth | +61.3% | -28.8% | +63.7% | +61.5% | -34.7% | +11.5% | +56.8% |
| Net income growth | +9.2% | +17.5% | +18.1% | +112.0% | -35.1% | +27.3% | - |
| Revenue CAGR (3Y) | +31.4% | +28.7% | +16.8% | +6.4% | +3.4% | +12.5% | +15.2% |
| EBITDA CAGR (3Y) | +27.2% | +22.2% | +10.8% | +1.1% | +6.5% | +43.0% | +48.4% |
| Profitability & leverage | |||||||
| Net income margin | +8.2% | +6.7% | +12.5% | +9.9% | +7.7% | +11.5% | +8.7% |
| Return on capital employed | +27.9% | +32.9% | +33.3% | +30.5% | +16.8% | +29.9% | +33.6% |
| Return on net worth | +22.8% | +23.6% | +24.8% | +23.0% | +12.7% | +22.7% | +21.7% |
| Debt / equity | 0.09 | 0.03 | 0.01 | 0.01 | 0.02 | 0.03 | 0.02 |
| Long-term debt / equity | 0.08 | 0.02 | 0.00 | 0.01 | 0.01 | 0.02 | 0.01 |
| Interest cover | 1.97 | 1.25 | 0.71 | 0.58 | 1.37 | 0.95 | 1.12 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 11.31 | 8.48 | 7.07 | 5.77 | 4.90 | 5.56 | 6.58 |
| Inventory turnover | 2.89 | 4.42 | 6.20 | 6.07 | 5.37 | 5.01 | 5.87 |
| Debtors turnover | 11.42 | 10.16 | 9.94 | 10.37 | 9.42 | 9.66 | 10.21 |
| EPS (₹) | 75.01 | 46.30 | 64.60 | 39.72 | 24.64 | 37.32 | 28.88 |
| Dividend per share (₹) | 36.00 | 32.00 | 24.00 | 16.00 | 10.00 | 2.00 | 1.00 |
| Book value per share (₹) | 349.12 | 308.14 | 284.77 | 235.48 | 204.56 | 182.47 | 145.78 |
To see the full year-wise statements and ratios of Astrazeneca Pharma India Limited, buy the company report.
Board of directors of Astrazeneca Pharma India Limited
Astrazeneca Pharma India has 6 current directors and 35 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Shilpa Divekar Nirula | Director | 29 Dec 2021 | 4 Years 10 Months | Current |
| Ashok Revathy Also directs: Strategygarage Solutions LLP, United Foodbrands Limited, Digitide Solutions Limited and 5 more | Director | 02 Dec 2016 | 9 Years 11 Months | Current |
| Praveen Rao Akkinepally Also directs: Astrazeneca India Private Limited | Managing Director | 01 Jul 2025 | 1 Years 4 Months | Current |
| Monica | Director | 25 Sep 2024 | 2 Years 1 Months | Current |
| Bhavana Agrawal | Whole-Time Director | 08 Feb 2024 | 2 Years 9 Months | Current |
| Hooi Bien Chuah | Director | 09 Nov 2023 | 3 Years 0 Months | Current |
Peer comparison
Astrazeneca Pharma India Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Astrazeneca Pharma India Limitedthis company | ₹2,275.58 Cr (FY 2026) | ₹191.31 Cr | 8.4% | 32.6% | 935 | Bangalore, Karnataka, India |
| FDC Limited | ₹2,198.78 Cr (FY 2025) | 8.0% | Mumbai, Maharashtra, India | |||
| Unichem Laboratories Limited | ₹2,146.29 Cr (FY 2025) | 18.0% | Mumbai, Maharashtra, India | |||
| Caplin Point Laboratories Limited | ₹2,033.9 Cr (FY 2025) | 15.0% | Chennai, Tamil Nadu, India | |||
| Indoco Remedies Limited | ₹1,670.37 Cr (FY 2025) | -9.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Astrazeneca Pharma India Limited, buy the company report.
Auditor
Astrazeneca Pharma India Limited is audited by Price Waterhouse & Co Chartered Accountants LLP for the financial year 2025.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Price Waterhouse & Co Chartered Accountants LLP | FY 2025 | 304026E/E-300009 |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 75.00%, foreign institutional investors hold 2.70%, domestic institutional investors hold 6.10% and retail and other public shareholders hold 16.20%.
Sep 2026
QUARTER
75.00% Promoters
6.10% DII (Domestic Institutional)
2.70% FII (Foreign Institutional)
16.20% Retail & Others
Promoter holding - history
Now 75.00% · Sep 2026High 75.00% · Dec 2025Low 75.00% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 75.00% | 75.00% | 75.00% | 75.00% |
| Public | 25.00% | 25.00% | 25.00% | 25.00% |
Charges & borrowings
Open charges
None
Satisfied charges
₹62.5 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 16 Jan 2008 | 10083046 | Il & Fs Trust Company Limited | ₹62.5 Cr | Satisfied |
To see the full charge records of Astrazeneca Pharma India Limited, buy the company report.
Total charge records: 1 View all charges
Deals & funding
Astrazeneca Pharma India Limited has 8 deals on record (7 market trades, 1 acquisition); the latest was in October 2024.
Total deals
8
Market trades
7
Acquisition
1
Deals on record (5 of 8)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Oct 2024 | Market trade | ₹98.72 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| Sep 2024 | Market trade | ₹99.22 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| Sep 2024 | Market trade | ₹98.57 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| Jan 2017 | Acquisition | Undisclosed | Buyer: Zydus Lifesciences Limited Seller: Astrazeneca Pharma India Limited |
| May 2013 | Market trade | ₹10.67 Cr | Seller: Crosseas Capital Markets Private Limited |
To see the full deal history of Astrazeneca Pharma India Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Astrazeneca Pharma India Limited has 276 court cases on record: 150 filed by Astrazeneca Pharma India, 126 filed against it. 50 cases are pending and 226 are disposed.
Total cases
276
Filed by the company
150
Filed against the company
126
Pending
50
Disposed
226
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 185 | 83 | 29 |
| District courts | 87 | 40 | 19 |
| Supreme Court | 2 | 1 | 0 |
| NCLAT | 2 | 2 | 2 |
Cases on record (5 of 276)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Ahmedabad, Gujarat | Commercial matter | Filed against the company by Lubi Projects Private Limited | Disposed |
| District court, Maharashtra Industrial and Lab, Maharashtra | Court case (Ref IDA) | Filed against the company by an individual | Pending |
| District court, Central, Delhi | Court case (L I R) | Filed against the company by individuals | Pending |
| High Court of Delhi | Writ petition | Filed by the company against National Pharmaceutical Pricing Authority Department of Pharmaceuticals & Anr. | Pending |
| District court, BENGALURU, Karnataka | Appeal | Filed by the company against an individual | Pending |
To see the full case history of Astrazeneca Pharma India Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Astrazeneca Pharma India Limited has 11 MSME Form 1 returns on record between 2019 and 2024, listing 77 overdue payments to 29 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 29)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Kool - Ex Cold Chain Limited | |||
| an individual supplier | |||
| Zenith Leisure Holidays Limited | |||
| Saarathi Healthcare Private Limited | |||
| Healthlane Technologies Private Limited |
To see the full MSME payment records of Astrazeneca Pharma India Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Astrazeneca Pharma India Limited has a workforce of 935 employees on its EPFO records as of Apr 07, 2024, across 2 active EPFO establishments.
Employee count
935
Active EPFO establishments
2
Employee growth
-13.59%
GST
Astrazeneca Pharma India has 22 GST registrations: 11 active and 11 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
22
Active
11
Cancelled / inactive
11
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AABCA1722B1ZC | Karnataka | Active | 01 Jul 2017 |
| 04AABCA1722B1ZO | Chandigarh | Active | 01 Jul 2017 |
| 07AABCA1722B1ZI | Delhi | Active | 01 Jul 2017 |
| 18AABCA1722B2ZE | Assam | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Astrazeneca Pharma India Limited, buy the company report.
Recent activity
Astrazeneca Pharma India Limited has 63 board changes on record since 1979: 36 appointments and 27 cessations. The latest: Praveen Rao Akkinepally was appointed as Managing Director on 01 Jul 2025.
Filing
Astrazeneca Pharma India Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Bangalore.
AGM
Astrazeneca Pharma India Limited last Annual general meeting of members was held on 14 Aug 2025 as per latest MCA records.
Appointed
Praveen Rao Akkinepally was appointed as Managing Director.
Ceased
Sanjeev Kumar Panchal ceased to be Managing Director.
Appointed
Jesus Javier Diaz Ropero Esteso was appointed as Director.
Ceased
Narayan Keelveedhi Seshadri ceased to be Director.
Appointed
Monica was appointed as Director.
Ceased
Ankush Nandra ceased to be Director.
Appointed
Bhavana Agrawal was appointed as Whole-Time Director.
Ceased
Weiying Sarah Wang ceased to be Director.
Appointed
Sylvia Lorena Varela Ramon was appointed as Director.
Appointed
Hooi Bien Chuah was appointed as Director.
56 earlier events are in the company report.
News
ASTRAZEN: Q2 REVENUE 7.29B RUPEES VS 5.59B (YOY)
ASTRAZEN: Q2 EBITDA 955.7M RUPEES VS 751.8M (YOY); Q2 EBITDA MARGIN 13.11% VS 13.45% (YOY)
ASTRAZEN: Q2 STANDALONE NET PROFIT 623.3M RUPEES VS 542.2M (YOY)
Frequently asked questions
Astrazeneca Pharma India is an active public limited company based in Bangalore, Karnataka, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 11 July 1979 (47+ years old) and is registered under CIN L24231KA1979PLC003563. Listed on BSE: 506820 and NSE: ASTRAZEN.
Astrazeneca Pharma India reported revenue of ₹2,275.58 Cr for FY 2025-26 (up 32.6% YoY) based on standalone financials.
Astrazeneca Pharma India has 6 current directors:
- Praveen Rao Akkinepally - Managing Director
- Bhavana Agrawal - Whole-Time Director
- Shilpa Divekar Nirula - Director
- Ashok Revathy - Director
- Monica - Director
- Hooi Bien Chuah - Director
The latest financial statements of Astrazeneca Pharma India on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 14 August 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Astrazeneca Pharma India is 29AABCA1722B1ZC, registered in Karnataka. The company has 22 GST registrations in all, of which 11 are active and 11 are cancelled or inactive. Other active GSTINs include 04AABCA1722B1ZO (Chandigarh), 07AABCA1722B1ZI (Delhi), 18AABCA1722B2ZE (Assam).
The CIN (Corporate Identification Number) of Astrazeneca Pharma India is L24231KA1979PLC003563. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Astrazeneca Pharma India is a listed company as per MCA records. Its shares are listed on both BSE (code: 506820) and NSE (symbol: ASTRAZEN).
Astrazeneca Pharma India has 276 court cases on record: 150 filed by the company and 126 filed against it. 50 are pending. Most are in the high courts.
Astrazeneca Pharma India was incorporated on 11 July 1979, making it 47+ years old. It is registered with the Registrar of Companies, Bangalore.
Astrazeneca Pharma India has 8 deals on record (7 market trades, 1 acquisition); the latest was in October 2024.
The peers of Astrazeneca Pharma India by revenue are FDC Limited, Unichem Laboratories Limited, Caplin Point Laboratories Limited, Indoco Remedies Limited, all in the Pharma industry (Formulations), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations).
Praveen Rao Akkinepally was appointed as Managing Director on 01 Jul 2025. Sanjeev Kumar Panchal ceased to be Managing Director on 30 Jun 2025. Jesus Javier Diaz Ropero Esteso was appointed as Director on 13 Nov 2024. Astrazeneca Pharma India has 63 board changes on record in total.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages